BII Start-up Stories: September
This September, while the rainy Danish summer turned Indian and employees returned fully to work from their vacations, the Danish media was busy broadcasting the life science news from BII's varied portfolio.
Start reading our September summary below!
On September 25th, Venture House alumni Notify Therapeutics , which aims to help infertile women who do not benefit from standard hormone treatment, announced that it has raised EUR 5M from Lundbeckfonden / Lundbeck Foundation, Biocapital, and +ND Capital. FemTech Insider and MedWatch also brought the story.
The first spin-out from BII's Bio Studio program, Biomia , shared on September 26th that they have secured USD 3M in pre-seed financing from BlueYard Capital , Amino Collective , and Nucleus Capital. The investment will allow Biomia to accelerate its development of plant-inspired, natural, and new-to-nature halogenated small molecule drug candidates and further build its biosynthetic manufacturing platform.
Current Venture House start-up Cymab announced on September 13th that it has received a Grand Solution Grant of DKK 12,3M from Innovationsfonden . Cymab will use the money from the grant to conduct, among others, in vivo proof of concept studies in mice that, over time, will enable them to move on to human studies.
At the beginning of September, BII presented the latest cohort of Venture House start-ups, which sparked a notable amount of press attention. F?devareWatch and vegconomist featured food-tech start-up Matr Foods, and AgriWatch published an article on ag-tech start-up Agrobiomics . The women's health start-up FimmCyte , jointly supported by BII and Ferring Pharmaceuticals , appeared in both FemTech Insider and MedWatch . Lastly, the oncology start-up Solid Therapeutics and health-tech start-up HHC Medical appeared in MedWatch .
Venture House alumni and biotech start-up Commit Biologics announced on September 1st that it is getting a new CEO, life science veteran Krishna Polu . Commit Biologics, which is developing a novel immunotherapy platform, welcomes Polu's vast experience in pipeline advancement and drug approvals across multiple therapeutic areas.
In mid-September, Venture House alumni Ousia Pharma shared the addition of former GN Hearing CFO Morten P. Toft to its board in February 2023. Toft brings a decade of experience from heavily R&D-focused GN Hearing to the ambitious therapeutics start-up.
Biotech start-up?Hervolution , formerly InProTher, has pivoted from developing a technology platform to aid in treating patients with HPV to developing cancer immunotherapies targeting human endogenous retroviruses. Instead of discarding its original platform technology, the team is negotiating its transfer to the newly founded?Loma Therapeutics , which is currently partaking in BII's Venture Lab program.
领英推荐
On September 6th, The UNIPRENEURS Initiative recognized the entrepreneurial spirit of 20 professors from all over Germany, among them ECRC researcher and Co-Founder of MyoPax Simone Spuler . MyoPax pioneers stem cell technology to develop regenerative therapies for previously incurable muscle diseases.
'Guld og Gr?nne Skove', a podcast from DR - Danmarks Radio examining whether the market can solve our planet's climate challenges featured recent Venture Lab acceptee and biotech start-up Visibuilt on September 12th. Founder Line Kloster Pedersen guested the podcast to discuss her invention of a road construction solution that replaces fossil ingredients in asphalt. Hear about Visibuilt's innovative approach from 25:30.
*When signing up for and sending you the newsletter, BioInnovation Institute will process your personal data. The processing will be conducted in accordance with our Privacy Policy, which can be accessed here .
BII offers help to early-stage start-ups within human health and planetary health. Find more information on our early-stage Venture Programs, our company-creation program Bio Studio, and your opportunity to become a resident in our vibrant life science community in the heart of Copenhagen.